Eupraxia Pharmaceuticals Inc. income statement

In fiscal 2025, Eupraxia Pharmaceuticals Inc. reported revenue of $0 and net income of −$38.6m, or −$1.03 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Eupraxia Pharmaceuticals Inc.: income statement, annual
Fiscal year	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	0	0
Research and development	20	16	21
General and administrative	7	11	17
Interest expense	1	1	0
Income before tax	−29	−26	−39
Income tax	0	0	0
Net income	−28	−26	−39
Diluted EPS	−$1.17	−$0.76	−$1.03
Diluted shares (average)	24m	34m	40m

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Eupraxia Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Eupraxia Pharmaceuticals Inc.